KR101258696B1 - Health Suppliment Food Comprising Powder of Angelica Keiskei With Antioxdative Activity And Manufacturing Method Thereof - Google Patents
Health Suppliment Food Comprising Powder of Angelica Keiskei With Antioxdative Activity And Manufacturing Method Thereof Download PDFInfo
- Publication number
- KR101258696B1 KR101258696B1 KR1020100103588A KR20100103588A KR101258696B1 KR 101258696 B1 KR101258696 B1 KR 101258696B1 KR 1020100103588 A KR1020100103588 A KR 1020100103588A KR 20100103588 A KR20100103588 A KR 20100103588A KR 101258696 B1 KR101258696 B1 KR 101258696B1
- Authority
- KR
- South Korea
- Prior art keywords
- fresh vinegar
- antioxidant activity
- dietary supplement
- powder
- antioxidant
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 55
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 title claims description 9
- 230000036541 health Effects 0.000 title description 5
- 230000000694 effects Effects 0.000 title description 4
- 241001105098 Angelica keiskei Species 0.000 title description 2
- 239000000052 vinegar Substances 0.000 claims abstract description 97
- 235000021419 vinegar Nutrition 0.000 claims abstract description 97
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 80
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 239000000049 pigment Substances 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 235000007164 Oryza sativa Nutrition 0.000 claims description 5
- 235000013736 caramel Nutrition 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- 235000009566 rice Nutrition 0.000 claims description 5
- 235000020238 sunflower seed Nutrition 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 4
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000008429 bread Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 abstract description 29
- 238000010521 absorption reaction Methods 0.000 abstract description 19
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- 208000001145 Metabolic Syndrome Diseases 0.000 description 29
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 29
- 235000006708 antioxidants Nutrition 0.000 description 28
- 239000008047 antioxidant nutrient Substances 0.000 description 23
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 20
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 19
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 19
- 239000001656 lutein Substances 0.000 description 19
- 235000012680 lutein Nutrition 0.000 description 19
- 229960005375 lutein Drugs 0.000 description 19
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 19
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 19
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 19
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 18
- 235000013734 beta-carotene Nutrition 0.000 description 14
- 239000011648 beta-carotene Substances 0.000 description 14
- 229960002747 betacarotene Drugs 0.000 description 14
- 230000036542 oxidative stress Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 235000021466 carotenoid Nutrition 0.000 description 9
- 150000001747 carotenoids Chemical class 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 208000017667 Chronic Disease Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- OENHQHLEOONYIE-BVZAMQQESA-N 9-cis-beta-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-BVZAMQQESA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 241000209094 Oryza Species 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 230000007067 DNA methylation Effects 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000011795 alpha-carotene Substances 0.000 description 3
- 235000003903 alpha-carotene Nutrition 0.000 description 3
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 3
- 235000019244 cryptoxanthin Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 239000004212 Cryptoxanthin Substances 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 2
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008789 oxidative DNA damage Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000233838 Commelina Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DMASLKHVQRHNES-FKKUPVFPSA-N beta-cryptoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C DMASLKHVQRHNES-FKKUPVFPSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-OUUYXACASA-N cis-lycopene Natural products CC(=CCCC(=CC=CC(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C=C(C)/CCC=C(C)C)/C)C)C)C OAIJSZIZWZSQBC-OUUYXACASA-N 0.000 description 1
- 238000003927 comet assay Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- JBYXPOFIGCOSSB-UQGDGPGGSA-N rumenic acid Chemical compound CCCCCC\C=C/C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-UQGDGPGGSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- -1 water or ethanol Chemical compound 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/44—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 항산화 활성을 가지는 신선초 분말을 포함하는 건강보조식품 및 이의 제조방법에 관한 것으로, 신선초 분말을 포함하는 항산화 활성을 가지는 건강보조식품에 대한 것이다.
본 발명에 따르면 신선초에 함유되어 있는 친수성 및 친유성 항산화 성분의 생체내 흡수율 및 생체이용성 효율이 우수하여 항산화능 증강효과가 높은 건강보조식품을 제공할 수 있다. The present invention relates to a health supplement comprising a fresh vinegar powder having an antioxidant activity and a manufacturing method thereof, and to a health supplement having an antioxidant activity including a fresh vinegar powder.
According to the present invention, the hydrophilic and lipophilic antioxidant components contained in fresh vinegar are excellent in the absorption rate and bioavailability in vivo, thereby providing a health supplement with high antioxidant activity enhancing effect.
Description
본 발명은 신선초 분말을 포함하여 항산화 활성을 가지는 건강보조식품 및 이의 제조방법에 관한 것이다.
The present invention relates to a health supplement food having an antioxidant activity, including fresh vinegar powder, and a preparation method thereof.
인체는 정상적인 대사 과정에서 지속적으로 활성 산소군을 생성하는데 이 활성산소군이 신체에 과량 축적되면 인체의 다불포화 지방산, 아미노산, DNA 등에 대해 산화적 손상을 유발하고, 이는 노화, 비만, 당뇨병, 심장질환, 백내장, 황반변성 등 산화적 스트레스와 관련된 만성질환을 유발할 수 있다. The human body continuously generates free radicals during normal metabolic processes. When these free radicals accumulate in the body, they cause oxidative damage to polyunsaturated fatty acids, amino acids, DNA, etc. in the body, which leads to aging, obesity, diabetes, and heart. It can lead to chronic diseases related to oxidative stress, such as disease, cataracts, and macular degeneration.
항산화영양소는 활성 산소군을 제거하는 역할을 하여 신체 내 과량의 활성 산소군의 축적을 방어하고 산화적 손상(스트레스) 및 이와 관련된 만성 질환을 방어하거나 지연시킬 수 있다. Antioxidant nutrients act to eliminate free radicals, thereby defending the accumulation of excess free radicals in the body, and can prevent or delay oxidative damage (stress) and related chronic diseases.
한편, 현재까지 이루어진 베타-카로틴 또는 비타민 E 등의 단일 항산화영양소, 또는 이들 항산화 영양소를 복합적으로 산화적 스트레스를 받고 있는 집단에게 섭취시킨 대규모 중재실험(intervention trials)에서는 놀랍게도 과량의 단일 항산화영양소의 섭취시 오히려 암이나 심장병의 발병율 및 사망률을 증가시키는 것이 보고되었다. 따라서, 인체의 항산화 방어체계는 단일 영양소에 의해서가 아니라 지용성 및 수용성 항산화 영양소의 균형이 잘 이루어져야 최적으로 작용할 수 있는 것이며, 단일 영양소를 과량으로 섭취시에는 독성을 초래할 위험성이 있다.
On the other hand, in large-scale intervention trials in which single antioxidant nutrients such as beta-carotene or vitamin E, or these antioxidant nutrients have been ingested in complex oxidative stress groups, surprisingly large amounts of single antioxidant nutrients are consumed. Rather, it has been reported to increase the incidence and mortality of cancer or heart disease. Therefore, the human body's antioxidant defense system is not by a single nutrient but a well-balanced fat-soluble and water-soluble antioxidant nutrient can work optimally, there is a risk of toxicity when ingesting a single nutrient in excess.
신선초(神仙草; Angelica keiskei , 명일엽, 신립초라고도 함)는 일본에서 기원한 다년생 식물로서 아시아 지역에서 의학적으로 중요한 약초로 여겨져 왔다. 신선초의 추출물을 이용한 동물실험에서 신선초 추출물은 위산분비를 억제하고, 암을 예방하며, 고혈압을 예방하는 것으로 보고되었다. 그러나, 신선초의 인체내에서의 항산화 기능을 밝힌 경우는 없다. 또한, 현재까지 신선초의 생리적 섭취후 신체내 항산화 영양소의 흡수 카이네틱 또는 항산화 기능의 변화는 보고되어 있지 않다. Shinseoncho (神仙 草; Angelica keiskei ( also known as dayflower , new herb) is a perennial plant originated in Japan and has been considered a medically important herb in Asia. In animal experiments with extracts of fresh vinegar, the fresh vinegar extract has been reported to inhibit gastric acid secretion, prevent cancer, and prevent hypertension. However, there is no case that the antioxidant function of fresh vinegar is revealed in the human body. In addition, no changes in the absorption kinetic or antioxidant function of antioxidant nutrients in the body after physiological intake of fresh vinegar have been reported.
신선초에 함유되어 있는 주요 카로티노이드는 베타-카로틴과 루테인인데, 베타-카로틴은 비타민 A로의 전환과 항산화 효능을 가지며 많은 역학 조사에서 베타-카로틴 섭취량과 혈액의 베타-카로틴 농도는 암 발병률 및 심혈관 질환과 역의 상관관계가 있음이 보고되었다. 루테인은 안구 황반의 주요 구성성분이며 안구 수정체에서 발견되는 유일한 카로티노이드로 황반변성, 백내장 등의 안구 질환을 예방하는 것으로 알려져 있다. 신선초에는 또한 비타민 C가 풍부한데, 비타민 C는 많은 효소의 보조인자로 작용하는 필수 영양소로 전자공여능력과 재생능력이 뛰어나 효과적인 항산화 영양소로 알려져 있으며 수용성 환경에서 작용한다. 집단연구에서 비타민 C의 충분한 섭취는 심장질환, 암, 안질 및 퇴행성 뇌질환과 같은 많은 만성질환의 위험률을 낮춰주는 것으로 나타났다. 신선초에는 쿼시틴과 같은 폴리페놀 역시 풍부하게 함유되어 있는데, 동물과 인간 세포 배양실험 결과 폴리페놀은 심혈간질환, 암, 퇴행성 뇌질환, 당뇨병 및 골다공증을 예방한다고 알려져 있다. 게다가 항산화 및 항염증 특성 때문에 류마티즘성 관절염과 만성 폐색성 폐질환과 같은 산화적 스트레스나 염증을 포함한 다른 만성질환에도 유익한 영향을 주는 것으로 기대되고 있다.
The main carotenoids contained in fresh vinegar are beta-carotene and lutein, which have the effect of converting to vitamin A and antioxidant effects. Inverse correlations have been reported. Lutein is a major constituent of the ocular macula and is the only carotenoid found in the ocular lens. It is known to prevent eye diseases such as macular degeneration and cataracts. Fresh vinegar is also rich in vitamin C. Vitamin C is an essential nutrient that acts as a cofactor of many enzymes. It is known as an effective antioxidant nutrient because of its excellent electron donating ability and regenerative ability. Population uptake of vitamin C has been shown to reduce the risk of many chronic diseases, such as heart disease, cancer, eye disease and degenerative brain disease. Fresh vinegar is also rich in polyphenols, such as quasi-tin. Animal and human cell cultures have shown that polyphenols prevent cardiovascular disease, cancer, degenerative brain disease, diabetes and osteoporosis. In addition, antioxidant and anti-inflammatory properties are expected to have beneficial effects on other chronic diseases, including oxidative stress and inflammation, such as rheumatoid arthritis and chronic obstructive pulmonary disease.
본 발명자들은, 신선초의 주요 영양소에 대한 연구를 수행함으로써 신선초 내에 항산화 영양소인 카로티노이드, 비타민 C 및 페놀이 다량 함유되어 있고, 혈당과 혈지방을 조절하는 기능을 가진 칼콘 또한 풍부하다는 것을 알아내었으며, 이러한 신선초의 항산화능이 매우 우수하다는 것을 알아내었다. 이에 따라, 신선초를 이용하여 부작용이 없으면서 항산화능 증강 효과가 높은 건강보조식품을 개발하게 되었다.
The present inventors have conducted studies on the major nutrients of fresh vinegar and found that the fresh vinegar contains a large amount of antioxidant carotenoids, vitamin C and phenol, and is also rich in chalcones, which have functions to regulate blood sugar and blood fat, It was found that the antioxidant activity of these fresh vinegar is very good. Accordingly, using the fresh vinegar has been developed a health supplement food with a high antioxidant effect without any side effects.
본 발명은 신선초 분말을 포함하는 항산화 활성을 가지는 건강보조식품 및 이의 제조방법을 제공하고자 한다.The present invention is to provide a dietary supplement and a method for preparing a health supplement having antioxidant activity, including fresh vinegar powder.
본 발명은 부작용이 없으면서 신선초에 함유되어 있는 친수성 및 친유성 항산화 성분의 생체내 흡수율 및 생체이용성 효율이 우수하여 항산화능 증강효과가 높은 건강보조식품을 제공하고자 한다.
The present invention is to provide a health supplement with high anti-oxidation enhancing effect with excellent in vivo absorption rate and bioavailability of the hydrophilic and lipophilic antioxidant components contained in fresh vinegar without side effects.
상기 목적을 달성하기 위한 본 발명은 신선초 분말을 포함하는 항산화 활성을 가지는 건강보조식품을 제공한다.
The present invention for achieving the above object provides a dietary supplement with antioxidant activity, including fresh vinegar powder.
또한, 상기 신선초 분말은 진공동결건조 방법에 따라 제조된 것인 항산화 활성을 가지는 건강보조식품을 제공한다.
In addition, the fresh vinegar powder provides a health supplement with antioxidant activity that is prepared according to the vacuum freeze drying method.
또한, 상기 신선초 분말의 크기는 50 내지 250 메쉬인 것을 특징으로 하는 항산화 활성을 가지는 건강보조식품을 제공한다.
In addition, the size of the fresh vinegar powder provides a dietary supplement with antioxidant activity, characterized in that 50 to 250 mesh.
또한, 상기 신선초 분말을 0.5~30중량%의 함량으로 포함하는 것인 항산화 활성을 가지는 건강보조식품을 제공한다.
In addition, it provides a health supplement with antioxidant activity that comprises the fresh vinegar powder in an amount of 0.5 to 30% by weight.
또한, 식품학적으로 허용가능한 식품보조 첨가제를 더 함유하는 항산화 활성을 가지는 건강보조식품을 제공한다.
The present invention also provides a dietary supplement having antioxidant activity further containing a foodstuff acceptable dietary supplement.
또한, 분말, 과립, 정제, 캡슐, 음료 또는 빵류 형태인 항산화 활성을 가지는 건강보조식품을 제공한다.
In addition, it provides a dietary supplement with antioxidant activity in the form of powder, granules, tablets, capsules, beverages or bread.
또한, 신선초 분말 10~20중량%, 쌀가루 10~20중량%, 카라멜 색소 5~10중량%, 맥아이온엿 25~30중량%, 과당 10~15중량%, 포도당 10~15중량%, 말토덱스트린 1~5중량%, 해바라기씨유 3~10중량%, 레시틴 0.05~1중량%를 포함하는 항산화 활성을 가지는 건강보조식품을 제공한다.
In addition, 10-20% by weight of fresh vinegar powder, 10-20% by weight of rice flour, 5-10% by weight of caramel pigment, 25-30% by weight of Macion syrup, 10-15% by weight fructose, 10-15% by weight of glucose, maltodextrin It provides a dietary supplement with antioxidant activity comprising 1 to 5% by weight, sunflower seed oil 3 to 10% by weight, lecithin 0.05 to 1% by weight.
본 발명은 또한, (S1) 신선초를 세척하고 절단하는 단계; (S2) 절단된 신선초를 동결시키는 단계; (S3) 동결된 신선초를 건조시키는 단계; 및 (S4) 건조된 신선초를 분쇄하는 단계를 포함하는 항산화 활성을 가지는 건강보조식품의 제조방법을 제공한다.
The invention also, (S1) washing and cutting the fresh vinegar; (S2) freezing the cut fresh vinegar; (S3) drying the frozen fresh vinegar; And (S4) provides a method for producing a dietary supplement with antioxidant activity comprising the step of crushing the dried fresh vinegar.
또한, (S2)단계는 -80℃~-40℃에서 12~36시간 동안 수행되는 것인 항산화 활성을 가지는 건강보조식품의 제조방법을 제공한다.
In addition, (S2) step provides a method for producing a dietary supplement with antioxidant activity that is performed for 12 to 36 hours at -80 ℃ ~ -40 ℃.
또한, (S3)단계는 45℃~48℃에서 35~38시간 동안 수행되는 것인 항산화 활성을 가지는 건강보조식품의 제조방법을 제공한다.
In addition, (S3) step provides a method for producing a dietary supplement with antioxidant activity that is performed for 35 to 38 hours at 45 ℃ ~ 48 ℃.
또한, (S4)단계는 60%~65%로 습도가 조절된 상태에서 수행되는 것인 항산화 활성을 가지는 건강보조식품의 제조방법을 제공한다. In addition, (S4) step provides a method of producing a dietary supplement with antioxidant activity that is carried out in a condition of 60% ~ 65% humidity is controlled.
이하, 본 발명을 더욱 상세히 설명한다.
Hereinafter, the present invention will be described in more detail.
본 발명에 따르면 신선초에 함유되어 있는 친수성 및 친유성 항산화 성분(영양소)의 생체내 흡수율 및 생체이용성 효율이 우수하여 항산화능 증강효과가 높은 건강보조식품을 제공할 수 있다.
According to the present invention, the hydrophilic and lipophilic antioxidant components (nutrients) contained in fresh vinegar are excellent in the absorption rate and bioavailability of the present invention can provide a health supplement food with high antioxidant activity enhancing effect.
이러한 건강보조식품은 정상인뿐만 아니라 산화적 스트레스가 높은 대사성 증후군 환자의 항산화 영양소의 혈중 농도 및 체내 항산화기능이 증가시켜, 산화적 스트레스가 상승되는 노년층, 알츠하이머병, 파킨슨병, 뇌졸중, 헌팅턴병 및 치매와 같은 산화적 스트레스로 인한 질환을 가진 환자, 비만 및 만성질환자의 산화적 스트레스 저하 및 항산화 기능 향상 등을 위해 사용될 수 있다.
These dietary supplements increase the blood levels of antioxidant nutrients and the body's antioxidant function in normal as well as metabolic syndrome patients with high oxidative stress. It may be used for the reduction of oxidative stress and antioxidant function of patients with diseases such as oxidative stress, obesity and chronic diseases.
도 1은 본 발명의 일 실시예에 따른 건강보조식품의 제조과정을 나타내는 모식도이고,
도 2a는 본 발명의 일 실험예에 따라 추출 조건을 달리한 각각의 신선초 추출물의 친유성 항산화성분의 함량을 나타내는 그래프이며, 도 2b는 추출 조건을 달리한 각각의 신선초 추출물의 친수성 항산화성분의 함량을 나타내는 그래프이고,
도 3은 본 발명의 일 실험예에 따른 신선초 분말에 포함된 항산화 성분의 저장온도에 따른 안정성을 나타내는 그래프로서, 도 3a는 루테인(Lutein), 도 3b는 트랜스 베타-카로틴(trans β-carotene), 도 3c는 9-시스 베타-카로틴(9-cis β-carotene), 도 3d는 토탈 페놀(Total phenols)에 대한 그래프이며,
도 4a는 본 발명의 일 실시예에 따른 신선초 분말을 포함하는 건강보조식품 섭취 후의 정상건강인의 혈액내 쿼시틴 함량 변화를 나타내는 그래프이고, 도 4b는 상기 건강보조식품 섭취 후의 대사성 증후군 환자의 혈액내 쿼시틴 함량 변화를 나타내는 그래프이며,
도 5a는 본 발명의 일 실시예에 따른 신선초 분말을 포함하는 건강보조식품 섭취 후의 정상건강인의 혈액내 베타-카로틴 흡수 카이네틱을 나타내는 그래프이고, 도 5b는 상기 건강보조식품 섭취 후의 정상건강인의 루테인의 흡수 카이네틱을 나타내는 그래프이며,
도 6a는 본 발명의 일 실시예에 따른 신선초 분말을 포함하는 건강보조식품 섭취 후의 대사성 증후군 환자의 혈액내 베타-카로틴 흡수 카이네틱을 나타내는 그래프이고, 도 5b는 상기 건강보조식품 섭취 후의 대사성 증후군 환자의 루테인의 흡수 카이네틱을 나타내는 그래프이며,
도 7a는 본 발명의 일 실시예에 따른 신선초 분말을 포함하는 건강보조식품 섭취 후의 정상건강인의 혈액내 항산화 기능 카이네틱을 나타내는 그래프이고, 도 7b는 상기 건강보조식품 섭취 후의 대사성 증후군 환자의 혈액내 항산화 기능 카이네틱을 나타내는 그래프이다.1 is a schematic diagram showing a manufacturing process of the health supplement according to an embodiment of the present invention,
Figure 2a is a graph showing the content of the lipophilic antioxidant component of each fresh vinegar extract with different extraction conditions in accordance with an experimental example of the present invention, Figure 2b is the content of the hydrophilic antioxidant component of each fresh vinegar extract with different extraction conditions Is a graph representing
Figure 3 is a graph showing the stability according to the storage temperature of the antioxidant component contained in fresh vinegar powder according to an experimental example of the present invention, Figure 3a is lutein (Lutein), Figure 3b is trans beta-carotene (trans β-carotene) 3c is a 9-cis beta-carotene (9-cis β-carotene), 3d is a graph for total phenols,
Figure 4a is a graph showing the change in the content of quasi-citin in the blood of a normal healthy person after intake of a dietary supplement containing fresh vinegar powder according to an embodiment of the present invention, Figure 4b is a blood of the patient of metabolic syndrome after intake of the dietary supplement It is a graph showing the change of the quasi-tin content in
Figure 5a is a graph showing the beta-carotene absorption kinetic in the blood of the normal health person after intake of dietary supplement containing fresh vinegar powder according to an embodiment of the present invention, Figure 5b is normal health after intake of the dietary supplement Graph showing phosphorus lutein absorption kinetics,
Figure 6a is a graph showing the beta-carotene absorption kinetics in the blood of the metabolic syndrome patient after intake of dietary supplement containing fresh vinegar powder according to an embodiment of the present invention, Figure 5b is a metabolic syndrome after intake of the dietary supplement Is a graph showing the absorption kinetic of lutein in the patient,
Figure 7a is a graph showing the antioxidant function kinetics in the blood of normal healthy people after intake of dietary supplement containing fresh vinegar powder according to an embodiment of the present invention, Figure 7b is a metabolic syndrome patient after the dietary supplement intake It is a graph showing the antioxidant function kinetics in the blood.
본 발명은 신선초 분말을 포함하는 항산화 활성을 가지는 건강보조식품에 관한 것이다.The present invention relates to a health supplement having antioxidant activity, including fresh vinegar powder.
본 발명에 따른 신선초는 잎과 잎줄기 부분을 사용하는 것이 바람직하다. Fresh vinegar according to the present invention is preferably to use the leaves and the stem part.
그리고, 상기 신선초는 물 또는 에탄올과 같은 알코올로 추출하는 경우에는 지용성 항산화 영양소의 추출 효율이 낮아 영양소의 손실이 발생하므로 진공동결건조시켜 분말로 제조되는 것이 바람직하다. 보다 구체적으로, 본 발명의 신선초 분말은 신선초를 -80℃~-40℃에서 12~36시간 동안 동결시킨 후, 45℃~48℃에서 35~38시간 동안 진공건조시킨 다음 분쇄하여 제조된 것이 바람직하다. 또한, 동결건조시킨 신선초를 분쇄할 때에는 흡습을 방지하기 위해서 60%~65%로 습도가 조절된 상태에서 분쇄하는 것이 바람직하다. 상기와 같은 진공동결건조 조건은 영양소 파괴를 최소화하고 신선초에 함유되어 있는 항산화 영양소의 생체내 흡수율 및 생체이용성 효율을 향상시키기에 바람직하다.In addition, when the fresh vinegar is extracted with alcohol such as water or ethanol, the extraction efficiency of fat-soluble antioxidant nutrients is low, so that loss of nutrients occurs, and it is preferable to prepare the powder by vacuum freeze drying. More specifically, the fresh vinegar powder of the present invention is prepared by freezing the fresh vinegar for 12-36 hours at -80 ℃ ~ -40 ℃, vacuum dried at 45 ℃ ~ 48 ℃ for 35 to 38 hours and then pulverized Do. In addition, when pulverizing the fresh lyophilized fresh vinegar, it is preferable to grind in a state where the humidity is controlled to 60% to 65% in order to prevent moisture absorption. The vacuum freeze drying conditions as described above are preferable to minimize nutrient destruction and to improve the in vivo absorption rate and bioavailability efficiency of antioxidant nutrients contained in fresh vinegar.
상기 신선초 분말은 50 내지 250 메쉬 크기인 것이 바람직하며, 80 메쉬 크기인 것이 더욱 바람직하다. 분말의 크기가 너무 작으면 경제적이지 않고, 너무 크면 식감이 좋지 않을 수 있다.The fresh vinegar powder is preferably 50 to 250 mesh size, more preferably 80 mesh size. If the size of the powder is too small, it is not economical. If the powder is too large, the texture may be poor.
그리고, 본 발명의 건강보조식품에 포함되는 신선초 분말의 함량은 0.5~30중량%인 것이 바람직하다. 신선초 분말의 항산화 효능이 발현되기 위해서는 상기 함량 범위인 것이 바람직하다. 또한, 본 발명에 따른 건강보조식품에는 신선초 분말이 1일 적정섭취량인 3g~6g의 함량으로 포함되어 있는 것이 바람직하다.
And, the content of fresh vinegar powder contained in the health supplement of the present invention is preferably 0.5 to 30% by weight. In order to express the antioxidant efficacy of fresh vinegar powder is preferably in the above content range. In addition, it is preferable that the dietary supplement according to the present invention contains fresh vinegar powder in an amount of 3 g to 6 g, which is a proper daily intake.
상기한 본 발명의 건강보조식품은 분말, 과립, 정제, 캡슐, 음료 또는 빵류 등의 형태로 제조될 수 있다. 그리고, 건강보조식품을 상기 형태로 제조하는 과정에서 신선초 분말 외에 당류, 색소류와 같은 식품학적으로 허용가능한 식품보조 첨가제를 더 함유시킬 수 있다.
The health supplement of the present invention can be prepared in the form of powder, granules, tablets, capsules, beverages or bread. Further, in the process of preparing the health supplement food in the above form, in addition to the fresh vinegar powder, it may further contain food acceptable additives such as sugars, pigments.
본 발명에 따른 건강보조식품의 바람직한 일 구현예로는 신선초 분말 10~20중량%, 쌀가루 10~20중량%, 카라멜 색소 5~10중량%, 맥아이온엿 25~30중량%, 과당 10~15중량%, 포도당 10~15중량%, 말토덱스트린 1~5중량%, 해바라기씨유 3~10중량%, 레시틴 0.05~1중량%를 포함하는 정제 형태의 건강보조식품이 있다. 이와 같은 건강보조식품은 항산화능 증강효과가 높을 뿐만 아니라 일상 생활 속에서 간편하게 복용이 가능하다.
As a preferred embodiment of the health supplement according to the
본 발명에 따른 건강보조식품은 신선초에 함유되어 있는 친수성 및 친유성 항산화 성분의 생체내 흡수율 및 생체이용성 효율이 우수하여 항산화능 증강효과가 높다. 이와 같은 건강보조식품은 정상인뿐만 아니라 산화적 스트레스가 높은 대사성 증후군 환자의 항산화 영양소의 혈중 농도 및 체내 항산화기능이 증가시켜, 산화적 스트레스가 상승되는 노년층, 알츠하이머병, 파킨슨병, 뇌졸중, 헌팅턴병 및 치매와 같은 산화적 스트레스로 인한 질환을 가진 환자, 비만 및 만성질환자의 산화적 스트레스 저하 및 항산화 기능 향상 등을 위해 사용될 수 있다. 이외에도, 본 발명에 따른 건강보조식품은 대사성 증후군과 관련된 여러 가지 질환의 예방 및 개선에 효과적일 수 있다.
The health supplement according to the present invention is excellent in the absorption rate and bioavailability efficiency of the hydrophilic and lipophilic antioxidant components contained in fresh vinegar and has a high antioxidant activity enhancing effect. These dietary supplements increase the blood levels of antioxidant nutrients and the body's antioxidant function in normal as well as metabolic syndrome patients with high oxidative stress, and thus elevate oxidative stress in elderly people, Alzheimer's disease, Parkinson's disease, stroke, Huntington's disease and dementia. Patients with diseases caused by oxidative stress, such as obesity and chronic diseases can be used for reducing the oxidative stress and antioxidant function. In addition, the dietary supplement according to the present invention may be effective in preventing and improving various diseases related to metabolic syndrome.
다음으로, 본 발명은 (S1) 신선초를 세척하고 절단하는 단계; (S2) 절단된 신선초를 동결시키는 단계; (S3) 동결된 신선초를 건조시키는 단계; 및 (S4) 건조된 신선초를 분쇄하는 단계를 포함하는 항산화 활성을 가지는 건강보조식품의 제조방법을 제공한다.Next, the present invention (S1) washing and cutting the fresh vinegar; (S2) freezing the cut fresh vinegar; (S3) drying the frozen fresh vinegar; And (S4) provides a method for producing a dietary supplement with antioxidant activity comprising the step of crushing the dried fresh vinegar.
이때, (S2) 단계의 신선초 동결조건, (S3) 단계의 신선초 건조조건, (S4) 단계의 신선초 분쇄조건은 상기에서 기재한 바와 같다.
At this time, fresh vinegar freezing conditions of step (S2), fresh vinegar drying conditions of step (S3), fresh vinegar grinding conditions of step (S4) are as described above.
이하, 본 발명의 구성을 도면 및 실시예를 통하여 보다 상세히 설명하나, 본 발명의 범위가 하기 실시예로 한정되는 것은 아니다.
Hereinafter, the configuration of the present invention in more detail with reference to the drawings and examples, but the scope of the present invention is not limited to the following examples.
실시예Example
신선초 분말을 포함하는 건강보조식품의 제조과정을 도 1을 참조하여 설명한다.A manufacturing process of the dietary supplement containing fresh vinegar powder will be described with reference to FIG. 1.
먼저, 신선초의 잎과 잎줄기를 수확하여 신선한 부분을 검수, 선별하고 3회 세척하였다. 그리고, 세척한 신선초를 적당한 크기로 절단한 다음 -65℃에서 24시간 동안 동결시키고, 46℃에서 36시간 동안 진공건조시켰다. 건조가 완료된 신선초를 흡습 방지를 위하여 63%의 습도 환경에서 분쇄하여 80메쉬 크기의 신선초 분말을 제조하였다.First, the leaves and leaf stems of fresh vines were harvested, inspected, selected and washed three times with fresh portions. The washed fresh vinegar was cut to a suitable size and then frozen at −65 ° C. for 24 hours, and vacuum dried at 46 ° C. for 36 hours. The dried fresh vinegar was pulverized in a humidity environment of 63% to prevent moisture absorption to prepare a fresh mesh powder of 80 mesh size.
그리고, 맥아이온엿 45.2중량%, 과당 20.3중량%, 포도당 20.3 중량%, 말토덱스트린 6.2중량%, 해바라기씨유 7.84 중량% 및 레시틴 0.16 중량%을 혼합 탱크에 넣고 가온 및 교반하여 당액을 제조하였다. 제조된 당액 91.43 중량%와 카라멜색소 8.57 중량%를 혼합한 후, 색소가 혼합된 당액 70 중량%에 쌀가루 15 중량% 및 상기 제조된 신선초 분말 15 중량%를 혼합하여 정제 형태의 건강보조식품을 제조하였다.Then, 45.2% by weight of Macion syrup, 20.3% by weight fructose, 20.3% by weight glucose, 6.2% by weight maltodextrin, 7.84% by weight sunflower seed oil and 0.16% by weight of lecithin were added to a mixing tank to prepare a sugar solution. After mixing 91.43% by weight of the prepared sugar solution and 8.57% by weight of caramel pigment, 70% by weight of the sugar-mixed sugar solution was mixed with 15% by weight of rice flour and 15% by weight of the prepared fresh vinegar powder to prepare a dietary supplement. It was.
상기 건강보조식품은 맥아이온엿 28.9 중량%, 과당 15 중량%, 포도당 13 중량%, 말토덱스트린 4 중량%, 해바라기씨유 5 중량%, 레시틴 0.1 중량%, 카라멜색소 6중량%, 쌀가루 15중량% 및 본 발명에 따른 신선초 분말 15중량%로 구성되어 있고, 신선초 분말의 1일 적정 섭취량인 5g을 함유하고 있다.
The dietary supplement is 28.9% by weight Macion syrup, 15% by weight fructose, 13% by weight glucose, 4% by weight maltodextrin, 5% by weight sunflower seed oil, 0.1% by weight lecithin, 6% by weight caramel pigment, 15% by weight rice flour And 15% by weight of fresh vinegar powder according to the present invention, and contains 5 g of a proper intake amount of fresh vinegar powder per day.
실험예Experimental Example 1: 신선초 분말 이용의 타당성 및 저장 온도에 따른 안정성 1: Feasibility of using fresh vinegar powder and stability according to storage temperature
신선초에 함유되어 있는 항산화 영양소의 추출 효율을 비교하기 위하여, 100wt% 물, 40wt% 에탄올, 70wt% 에탄올로 신선초를 추출하였다. In order to compare the extraction efficiency of antioxidant nutrients contained in fresh vinegar, fresh vinegar was extracted with 100wt% water, 40wt% ethanol, 70wt% ethanol.
도 2a는 상기 추출 조건을 달리한 각각의 신선초 추출물의 친유성 항산화성분의 함량을 나타내는 그래프이며, 도 2b는 추출 조건을 달리한 각각의 신선초 추출물의 친수성 항산화성분의 함량을 나타내는 그래프이다. 상기 도 2에 나타낸 바와 같이, 신선초를 100wt%의 물로 추출한 경우에는 지용성 카로티노이드가 추출되지 않았다. 그리고, 70wt% 에탄올로 추출한 경우에는 신선초에 함유되어 있는 지용성 항산화 영양소의 추출 효율이 낮았다. 구체적으로, 신선초에 함유된 항산화 영양소 중에서 루테인은 46%, 토탈 페놀의 경우 45%만이 추출되었다. Figure 2a is a graph showing the content of the lipophilic antioxidant component of each fresh vinegar extract with different extraction conditions, Figure 2b is a graph showing the content of the hydrophilic antioxidant component of each fresh vinegar extract with different extraction conditions. As shown in FIG. 2, when the fresh vinegar was extracted with 100 wt% of water, the fat-soluble carotenoid was not extracted. When extracted with 70 wt% ethanol, the extraction efficiency of fat-soluble antioxidant nutrients contained in fresh vinegar was low. Specifically, only 46% of lutein and 45% of total phenol were extracted from antioxidant nutrients contained in fresh vinegar.
따라서, 본 발명에 따른 항산화 활성을 나타내는 건강보조식품의 제조시 신선초 추출물을 이용하기보다는 신선초 분말 전체를 이용하는 것이 효과적임을 알 수 있다.
Therefore, it can be seen that it is effective to use the whole fresh vinegar powder rather than using the fresh vinegar extract when preparing the health supplement showing the antioxidant activity according to the present invention.
또한, 건강보조식품에 함유되어 있는 항산화 영양소가 저장 기간 동안 손실될 우려가 있으므로, 신선초를 건조 분말화한 후 저장 온도를 달리하여 장기간 저장하면서 신선초에 함유된 항산화 영양소의 안전성을 알아보았다.In addition, the antioxidant nutrients contained in the dietary supplements may be lost during the storage period, and the safety of the antioxidant nutrients contained in the fresh vinegar while drying for a long time by varying the storage temperature after drying powdered fresh vinegar.
도 3은 본 발명에 따라 제조된 신선초 분말에 포함되어 있는 항산화 성분의 저장온도에 따른 안정성을 나타내는 그래프로서, 도 3a는 루테인(Lutein), 도 3b는 트랜스 베타-카로틴(trans β-carotene), 도 3c는 9-시스 베타-카로틴(9-cis β-carotene), 도 3d는 토탈 페놀(Total phenols)에 대한 그래프를 나타낸 것이다. 상기 도 3에 나타낸 바와 같이, 신선초 건조분말에 있는 대부분의 항산화 영양소는 베타-카로틴을 제외하고는 실온에서 1년 이상 장기 보관하여도 안정하였다. 상기 베타-카로틴은 신선초 분말을 냉장 보관하는 경우에는 4-5개월간은 안정하였다. 루테인의 경우에는 12개월 동안 안정되었고, 12개월 이후에야 그 감소량이 유의적으로 감소하였다. 3 is a graph showing the stability according to the storage temperature of the antioxidant component contained in the fresh vinegar powder prepared according to the present invention, Figure 3a is lutein (Lutein), Figure 3b is trans beta-carotene (trans β-carotene), Figure 3c shows a 9-cis beta-carotene (9-cis β-carotene), Figure 3d shows a graph for the total phenols (Total phenols). As shown in FIG. 3, most of the antioxidant nutrients in the fresh vinegar dry powder were stable even after long-term storage at room temperature except for beta-carotene. The beta-carotene was stable for 4-5 months when refrigerated fresh vinegar powder. Lutein was stable for 12 months, and after 12 months the decrease was significantly reduced.
따라서, 본 발명에 따른 신선초 분말에 함유된 항산화 영양소는 대부분 실온에서 안정됨을 알 수 있다.
Therefore, it can be seen that the antioxidant nutrients contained in the fresh vinegar powder according to the present invention are mostly stable at room temperature.
실험예Experimental Example 2: 연구대상자의 생의학적, 생화학적 특성 2: Biomedical and Biochemical Characteristics of Subjects
총 126명의 연구대상자를 모집, 121명을 사전 스크린하고, 총 40명에 대한 신체검사 및 다양한 혈액 검사 등을 통하여 자격을 갖춘 10명의 연구대상자(5명; 정상 건강인, 5명; 대사성 증후군 환자)를 선정하였다.
A total of 126 subjects were recruited, 121 were screened in advance, and 10 qualified subjects (5; normal healthy, 5; metabolic syndrome patients) through a physical examination and various blood tests on a total of 40. ) Was selected.
상기 연구에 참여하기로 선정된 5인의 정상 건강인은 정상 간 및 신장 기능, 정상 혈청 단백질 대사 및 정상 지방 대사를 보였고, 신장 결석, 급성 위염, 고지혈증, 당뇨병, 췌장 질병 등이 없었으며, 호르몬도 사용하지 않았고 체질량지수(Body mass index, BMI)가 30 이하였다. 또한, 비타민제, 카로테노이드 보충제는 연구 시작 6주전부터 섭취하지 않았다. Five healthy individuals selected to participate in the study showed normal liver and kidney function, normal serum protein metabolism and normal fat metabolism, no kidney stones, acute gastritis, hyperlipidemia, diabetes, pancreatic disease, and hormones. The body mass index (BMI) was less than 30. In addition, vitamins and carotenoid supplementation were not taken 6 weeks before the start of the study.
연구에 참여한 각 5인의 정상인 및 대사 증후군 환자의 자격요건을 하기 표 1에 나타내었다.
The eligibility of each of the five normal and metabolic syndrome patients involved in the study is shown in Table 1 below.
(n=5, >50yr)Normal people
(n = 5,> 50yr)
(n=5, >50yr)Metabolic syndrome patients
(n = 5,> 50yr)
W/H ratio ≤ 0.9 for M,
≤ 0.85 for FBMI 18.5-30 and
W / H ratio ≤ 0.9 for M,
≤ 0.85 for F
> 0.85 for FW / H ratio> 0.9 for M,
> 0.85 for F
DBP < 85 mmHg and
TG < 150 mg/dLSBP <130 mm Hg and
DBP <85 mmHg and
TG <150 mg / dL
DBP 85 mmHg or
TG 150 mg/dLSBP 130 mmHg or
DBP 85 mmHg or
TG 150 mg / dL
하기 표 2는 연구에 참여한 정상 건강인(n=5)과 대사성 증후군 환자(n=5)의 혈액내 고밀도-콜레스테롤(HDL 콜레스테롤), 저밀도-콜레스테롤(LDL 콜레스테롤), 혈당, 감염 인자(CRP, IL6) 등의 상태를 나타낸 것이다. 대사성 증후군 환자의 경우 정상인에 비해 혈중 고밀도 콜레스테롤의 농도가 유의적으로 낮았고, 중성지방이 유의적으로 높았으며, 아디포넥틴(adiponectin)이 낮았다.
Table 2 shows the high-density-cholesterol (HDL cholesterol), low-density-cholesterol (LDL cholesterol), blood glucose, infectious agents (CRP,) in the blood of normal healthy subjects (n = 5) and metabolic syndrome patients (n = 5) who participated in the study. IL6) and the like. Patients with metabolic syndrome had significantly lower concentrations of high-density cholesterol, higher triglycerides, and lower adiponectin than normal subjects.
하기 표 3은 연구에 참여한 정상 건강인(n=5)과 대사성 증후군 환자(n=5)의 혈액내 항산화영양소의 농도를 나타낸 것이다. 대사성 증후군 환자의 경우 정상인에 비해 혈중 크립토잔틴과 베타-카로틴의 농도가 유의적으로 낮았고, 유의적이지는 않았으나 루테인, 알파-토코페롤의 농도도 낮은 경향을 보였으며, 유릭산은 유의적으로 높았다.
Table 3 below shows the concentrations of antioxidant nutrients in blood of normal healthy subjects (n = 5) and metabolic syndrome patients (n = 5). In patients with metabolic syndrome, serum levels of cryptoxanthin and beta-carotene were significantly lower than those of normal subjects, but not significantly, but concentrations of lutein and alpha-tocopherol tended to be lower than those of normal subjects.
하기 표 4는 연구에 참여한 정상 건강인(n=5)과 대사성 증후군 환자(n=5)의 DNA 손상 및 DNA 메틸화 정도를 나타낸 것이다. 이때, 산화적 DNA 손상은 단세포 전기영동법(single cell gel electrophoresis)으로 분석하였고, DNA 메틸화는 액체크로마토그래피-질량분석기(LC-MS)로 분석하였다.Table 4 below shows the degree of DNA damage and DNA methylation of normal healthy subjects (n = 5) and metabolic syndrome patients (n = 5). At this time, oxidative DNA damage was analyzed by single cell gel electrophoresis, and DNA methylation was analyzed by liquid chromatography-mass spectrometry (LC-MS).
대사성 증후군 환자의 DNA는 정상 건강인에 비하여 유의적으로 손상되어 있는 것을 알 수 있다.
DNA of metabolic syndrome patients is found to be significantly damaged compared to normal healthy.
실험예Experimental Example 3: 신선초 함유 건강보조식품의 섭취에 따른 인체 3: human body following intake of health supplement food containing fresh vinegar 혈액내In the blood 쿼시틴의Quacithin 흡수 absorption 카이네틱Kinetic
나이 50세 이상의 정상 건강인(5인) 및 대사증후군 환자(5인)에게 신선초 분말 5g이 함유된 실시예의 건강보조식품을 섭취시키기 전과 섭취시킨 후 30분, 60분, 120분, 180분, 240분, 300분, 360분, 420분, 480분에 혈액을 채취하여 각각의 쿼시틴 양을 측정하였다. 이때, 혈액 내의 플라보노이드(Free + phase Ⅱ enzyme conjugated flavonoid) 양은 고속액체크로마토그래피(HPLC-ECD)로 분석하였다.
30 minutes, 60 minutes, 120 minutes, 180 minutes, before and after ingestion of the dietary supplement of the Example containing 5 g of fresh vinegar powder to normal healthy persons (5 persons) and metabolic syndrome patients (5 persons) over 50 years old. Blood was collected at 240 minutes, 300 minutes, 360 minutes, 420 minutes, and 480 minutes to determine the amount of each quacithin. At this time, the amount of flavonoids (Free + phase II enzyme conjugated flavonoids) in the blood was analyzed by high performance liquid chromatography (HPLC-ECD).
도 4a는 상기 실험에 따른 신선초 분말을 포함하는 건강보조식품 섭취 후의 정상건강인의 혈액내 쿼시틴 함량 변화를 나타내는 그래프이고, 도 4b는 상기 건강보조식품 섭취 후의 대사성 증후군 환자의 혈액내 쿼시틴 함량 변화를 나타내는 그래프이다. 상기 도 4에 나타낸 바와 같이, 신선초 분말이 포함된 건강보조식품을 섭취하였을 때, 건강 정상인의 경우에는 섭취 1시간 후부터 3시간까지, 6시간에서 8시간까지 혈액내 쿼시틴 양이 증가하였고, 대사성 증후군 환자의 경우에는 혈액내 쿼시틴 양이 섭취 30분후부터 증가하였으며 그 증가한 양은 섭취후 8시간까지 유지되었다.
Figure 4a is a graph showing the change in the content of the quasi-citin in the blood of normal healthy people after intake of the dietary supplement containing fresh vinegar powder according to the experiment, Figure 4b is the quasi-citin content in the blood of the patient with metabolic syndrome after intake of the dietary supplement Graph showing change. As shown in FIG. 4, when the dietary supplement containing the fresh vinegar powder was ingested, the amount of quacithin in the blood increased from 1 hour to 3 hours, 6 hours to 8 hours in normal healthy individuals, and metabolic. In the case of syndrome patients, the amount of quacithin in the blood increased after 30 minutes of ingestion, and the increase was maintained up to 8 hours after ingestion.
실험예 4: 신선초 함유 건강보조식품의 섭취에 따른 인체 혈액내 카로티노이드의 흡수 카이네틱Experimental Example 4: Absorption Kinetics of Carotenoids in Human Blood with Intake of Fresh Supplements
나이 50세 이상의 정상 건강인(5인) 및 대사증후군 환자(5인)에게 신선초 분말 5g이 함유된 실시예의 건강보조식품을 섭취시키기 전과 섭취시킨 후 30분, 60분, 120분, 180분, 240분, 300분, 360분, 420분, 480분에 혈액을 채취하여 각각의 카로티노이드 양을 측정하였다. 30 minutes, 60 minutes, 120 minutes, 180 minutes, before and after ingestion of the dietary supplement of the Example containing 5 g of fresh vinegar powder to normal healthy persons (5 persons) and metabolic syndrome patients (5 persons) over 50 years old. Blood was collected at 240, 300, 360, 420 and 480 minutes to determine the amount of each carotenoid.
연구대상자가 섭취한 신선초 분말 함유 건강보조식품은 하기 표 5에 나타낸 바와 같이 약 2mg의 루테인과 약 1mg의 베타-카로틴이 함유되어 있다.
The fresh vinegar powder-containing dietary supplement ingested by the study subject contained about 2 mg of lutein and about 1 mg of beta-carotene, as shown in Table 5 below.
혈액내 카로티노이드(루테인, 지아잔틴, 베타-카로틴, 알파-카로틴, 크립토잔틴, 라이코핀)의 측정은 폴크 방법(Folch method)을 이용하여 혈액내 지용성 성분을 추출하고, 고속액체크로마토그래피(reverse-phase HPLC system)을 이용하여 지용성 항산화영양소를 동시에 측정하였다.Measurement of carotenoids in the blood (lutein, zeaxanthin, beta-carotene, alpha-carotene, kryptoxanthin, lycopene) is carried out by extracting the fat-soluble components in the blood using the Folch method, and reverse-phase chromatography The oil soluble antioxidants were simultaneously measured using an HPLC system.
도 5a는 본 발명의 실시예에 따른 신선초 분말을 포함하는 건강보조식품 섭취 후의 정상건강인의 혈액내 베타-카로틴 흡수 카이네틱을 나타내는 그래프이고, 도 5b는 상기 건강보조식품 섭취 후의 정상건강인의 루테인의 흡수 카이네틱을 나타내는 그래프이다. Figure 5a is a graph showing the beta-carotene absorption kinetic in the blood of the normal health person after intake of dietary supplement containing fresh vinegar powder according to an embodiment of the present invention, Figure 5b is a normal health person after intake of the dietary supplement It is a graph showing the absorption kinetic of lutein.
상기 도 5에 나타낸 바와 같이, 정상 건강인의 경우 실시예의 건강보조식품을 섭취한 후 베타-카로틴의 혈중 농도가 증가하였으나 유의적이지는 않았다. 루테인의 혈중 농도는 섭취후 30분부터 유의적으로 증가하여 그 증가한 농도가 8시간까지 유지되었다.As shown in FIG. 5, the blood concentration of beta-carotene was increased after ingestion of the dietary supplement of the normal healthy subject, but was not significant. Lutein blood concentration increased significantly from 30 min after ingestion, and the increased concentration was maintained for up to 8 hours.
도 6a는 본 발명의 실시예에 따른 신선초 분말을 포함하는 건강보조식품 섭취 후의 대사성 증후군 환자의 혈액내 베타-카로틴 흡수 카이네틱을 나타내는 그래프이고, 도 5b는 상기 건강보조식품 섭취 후의 대사성 증후군 환자의 루테인의 흡수 카이네틱을 나타내는 그래프이다.Figure 6a is a graph showing the beta-carotene absorption kinetic in the blood of the metabolic syndrome patient after intake of dietary supplement containing fresh vinegar powder according to an embodiment of the present invention, Figure 5b is a metabolic syndrome patient after intake of the dietary supplement It is a graph showing the absorption kinetic of lutein.
상기 도 6에 나타낸 바와 같이, 대사성 증후군 환자의 경우에는 베타-카로틴의 혈중농도가 실시예의 건강보조식품을 섭취한 후 5시간부터 유의적으로 증가하여 8시간까지 유의적으로 높은 농도를 유지하였으며, 루테인의 혈중농도가 실시예의 건강보조식품을 섭취한 후 6시간부터 증가하여 8시간까지 높은 농도를 유지하였다.As shown in FIG. 6, in patients with metabolic syndrome, the blood concentration of beta-carotene was significantly increased from 5 hours after ingesting the dietary supplement of Example, and maintained significantly high concentration up to 8 hours. The blood concentration of lutein was increased from 6 hours after ingesting the dietary supplement of Example to maintain a high concentration up to 8 hours.
따라서, 정상 건강인과 대사성 증후군 환자 모두 실시예의 건강보조식품에 함유된 항산화 영양소인 카로티노이드의 흡수가 효율적인 것을 알 수 있다.
Therefore, it can be seen that both normal healthy people and patients with metabolic syndrome have an efficient absorption of carotenoids, which are antioxidant nutrients contained in the dietary supplements of Examples.
실험예Experimental Example 5: 신선초 함유 건강보조식품의 섭취에 따른 인체 5: Human body following intake of health supplement food containing fresh vinegar 혈액내In the blood 항산화 기능 Antioxidant function 카이네틱Kinetic
나이 50세 이상의 정상 건강인(5인) 및 대사증후군 환자(5인)에게 신선초 분말 5g이 함유된 실시예의 건강보조식품을 섭취시키기 전과 섭취시킨 후 30분, 60분, 120분, 180분, 240분, 300분, 360분, 420분, 480분에 혈액을 채취하여 이들 혈액내 총 항산화기능을 측정하였다.30 minutes, 60 minutes, 120 minutes, 180 minutes, before and after ingestion of the dietary supplement of the Example containing 5 g of fresh vinegar powder to normal healthy persons (5 persons) and metabolic syndrome patients (5 persons) over 50 years old. Blood was collected at 240, 300, 360, 420, and 480 minutes to determine the total antioxidant activity in these blood.
혈액내 총 항산화기능(Total antioxidant performance) 측정은 MeO-AMVN으로 산화를 유도한 다음, BODIPY의 산화 카이네틱을 형광성 스펙트로포토미터를 이용하여 측정하였다. Total antioxidant performance in blood was measured by induction of oxidation with MeO-AMVN, and then the oxidative kinetics of BODIPY were measured using a fluorescent spectrophotometer.
도 7a는 본 발명의 실시예에 따른 신선초 분말을 포함하는 건강보조식품 섭취 후의 정상건강인의 혈액내 항산화 기능 카이네틱을 나타내는 그래프이고, 도 7b는 상기 건강보조식품 섭취 후의 대사성 증후군 환자의 혈액내 항산화 기능 카이네틱을 나타내는 그래프이다. 상기 도 7에 나타낸 바와 같이, 정상 건강인의 경우 혈액내 총 항산화능이 실시예의 건강보조식품을 섭취한 후 1,3,6,7시간에 증가하였고, 대사성 증후군 환자의 경우에는 실시예의 건강보조식품을 섭취한 후 30분과 5시간에 증가하였다.
Figure 7a is a graph showing the antioxidant function kinetics in the blood of normal healthy people after intake of dietary supplement containing fresh vinegar powder according to an embodiment of the present invention, Figure 7b is a blood of the patient of metabolic syndrome after the dietary supplement intake It is a graph showing the antioxidant function kinetics. As shown in FIG. 7, the total antioxidant activity in blood was increased in 1,3,6,7 hours after ingesting the dietary supplement of Example, and in the case of patients with metabolic syndrome, the dietary supplement of Example Increased in 30 minutes and 5 hours after ingestion.
상기와 같이, 본 발명에 따른 신선초 분말 함유 건강보조식품을 섭취하는 경우 정상인뿐만 아니라 산화적 스트레스가 높은 대사성 증후군 환자의 항산화 영양소의 혈중 농도 및 체내 항산화기능이 증가하는 것을 알 수 있다. 본 발명에 따른 건강보조식품은 또한, 산화적 스트레스가 상승되는 노년층, 알츠하이머병, 파킨슨병, 뇌졸중, 헌팅턴병 및 치매와 같은 산화적 스트레스로 인한 질환을 가진 환자, 비만 및 만성질환자의 산화적 스트레스 저하 및 항산화 기능 향상에 바람직하다.As described above, it can be seen that the intake of fresh vinegar powder-containing dietary supplement according to the present invention increases the blood concentration and antioxidant function of the antioxidant nutrients in metabolic syndrome patients with high oxidative stress as well as normal people. The dietary supplement according to the present invention also reduces the oxidative stress of the elderly, Alzheimer's disease, Parkinson's disease, stroke, Huntington's disease and patients with diseases caused by oxidative stress such as dementia, obesity and chronic diseases, which are elevated oxidative stress. And antioxidant properties.
Claims (11)
Fresh vinegar powder 10-20 wt%, rice flour 10-20 wt%, caramel pigment 5-10 wt%, maion starch 25-30 wt%, fructose 10-15 wt%, glucose 10-15 wt%, maltodextrin 1 ~ Health supplement with antioxidant activity, including 5% by weight, sunflower seed oil 3-10% by weight and lecithin 0.05-1% by weight.
The dietary supplement with antioxidant activity of claim 1, wherein the fresh vinegar powder is prepared according to a vacuum freeze drying method.
The dietary supplement with antioxidant activity according to claim 1, wherein the size of the fresh vinegar powder is 50 to 250 mesh.
The dietary supplement with antioxidant activity of claim 1, comprising 0.5 to 30% by weight of fresh vinegar powder.
The dietary supplement with antioxidant activity of Claim 1 which further contains a foodstuff acceptable food supplement additive.
The dietary supplement of claim 1 having antioxidant activity in the form of a powder, granule, tablet, capsule, beverage or bread.
(S2) 절단된 신선초를 동결시키는 단계;
(S3) 동결된 신선초를 건조시키는 단계; 및
(S4) 건조된 신선초를 분쇄하는 단계를 포함하는 제1항의 항산화 활성을 가지는 건강보조식품의 제조방법.
(S1) washing and cutting fresh vinegar;
(S2) freezing the cut fresh vinegar;
(S3) drying the frozen fresh vinegar; And
(S4) A method of producing a health supplement food having the antioxidant activity of claim 1 comprising the step of crushing the dried fresh vinegar.
The method of claim 8, wherein (S2) step is carried out for 12 to 36 hours at -80 ° C ~ -40 ° C.
The method of claim 8, wherein (S3) step is carried out for 35 to 38 hours at 45 ℃ to 48 ℃ manufacturing method of health supplements having antioxidant activity.
The method of claim 8, wherein the step (S4) is 60% to 65% of the method of producing a dietary supplement with antioxidant activity that is carried out in a condition where the humidity is controlled.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100103588A KR101258696B1 (en) | 2010-10-22 | 2010-10-22 | Health Suppliment Food Comprising Powder of Angelica Keiskei With Antioxdative Activity And Manufacturing Method Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100103588A KR101258696B1 (en) | 2010-10-22 | 2010-10-22 | Health Suppliment Food Comprising Powder of Angelica Keiskei With Antioxdative Activity And Manufacturing Method Thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120042092A KR20120042092A (en) | 2012-05-03 |
KR101258696B1 true KR101258696B1 (en) | 2013-04-29 |
Family
ID=46262928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100103588A KR101258696B1 (en) | 2010-10-22 | 2010-10-22 | Health Suppliment Food Comprising Powder of Angelica Keiskei With Antioxdative Activity And Manufacturing Method Thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101258696B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160063941A (en) | 2014-11-27 | 2016-06-07 | (주)퓨젠바이오농업회사법인 | Antioxidant composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102040119B1 (en) * | 2017-05-25 | 2019-11-05 | 숙명여자대학교산학협력단 | A composition comprising the isolated compounds from an extract of Angelica keiskei for treating and preventing muscle-related disorder |
CN112674336A (en) * | 2020-12-21 | 2021-04-20 | 石家庄以岭药业股份有限公司 | Antioxidant composition and antioxidant health food |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050120535A (en) * | 2004-06-17 | 2005-12-22 | 샬롬산업(주) | Angelica powder juice and their manufacture method |
KR20060133050A (en) * | 2004-03-26 | 2006-12-22 | 산또리 가부시키가이샤 | Process for producing health food containing dietary fiber |
-
2010
- 2010-10-22 KR KR1020100103588A patent/KR101258696B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060133050A (en) * | 2004-03-26 | 2006-12-22 | 산또리 가부시키가이샤 | Process for producing health food containing dietary fiber |
KR20050120535A (en) * | 2004-06-17 | 2005-12-22 | 샬롬산업(주) | Angelica powder juice and their manufacture method |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160063941A (en) | 2014-11-27 | 2016-06-07 | (주)퓨젠바이오농업회사법인 | Antioxidant composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
KR20120042092A (en) | 2012-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Singletary | Kiwifruit: Overview of potential health benefits | |
Johnson et al. | Sweet potato leaves: properties and synergistic interactions that promote health and prevent disease | |
Pereira et al. | Characterization and antioxidant potential of Brazilian fruits from the Myrtaceae family | |
Giuberti et al. | The potential of Moringa oleifera in food formulation: A promising source of functional compounds with health-promoting properties | |
C Hunter et al. | Antioxidant and ‘natural protective’properties of kiwifruit | |
AU2006212035A1 (en) | Therapeutic uses of tomato extracts | |
Limtrakul et al. | Anthocyanins and proanthocyanidins in natural pigmented rice and their bioactivities | |
Farag et al. | Valorization and extraction optimization of Prunus seeds for food and functional food applications: A review with further perspectives | |
Sharma et al. | Sesame (Sesamum indicum) seed | |
García-Chacón et al. | Camu camu (Myrciaria dubia (Kunth) mcVaugh): an amazonian fruit with biofunctional properties–A review | |
WO2007142984A2 (en) | Nutritional formulations and associated methods | |
KR101258696B1 (en) | Health Suppliment Food Comprising Powder of Angelica Keiskei With Antioxdative Activity And Manufacturing Method Thereof | |
JP2010502572A (en) | Stable and bioavailable skin and hair compositions of carotenoid isomers | |
Christiansen et al. | Effects of Aronia melanocarpa on cardiometabolic diseases: A systematic review of quasi-design studies and randomized controlled trials | |
Garrido et al. | Characterization and trials of a jerte valley cherry product as a natural antioxidant-enriched supplement. | |
Correa et al. | Bioavailability of plant pigment phytochemicals in Angelica keiskei in older adults: A pilot absorption kinetic study | |
Winifred et al. | Biochemical studies of the ameliorating effects of bitter leaf and scent leaf extracts on diabetes mellitus in humans | |
KR102172316B1 (en) | A composition comprising rose flower extract for reducing body fat and a health functional food comprising the composition | |
KR20140036966A (en) | Composition for improving exercise capacity or a composition for reducing fatigue using leaves of sasa quelpaertensis | |
Blando et al. | Opuntia, ficus‐indica [L.] Mill. and Other Species: Source of Bioactives and Their Molecular Mechanisms of Action to Promote Human Health | |
Iyer et al. | Impact of Amla (Embilica Officinalis) supplementation on the glycemic and lipidemic status of type 2 diabetic subjects | |
JP7242219B2 (en) | Blood sugar elevation inhibitor, diabetes inhibitor, and food composition | |
ZARE et al. | Impact of consumption of chicory leaf extract in adjunct with non-surgical periodontal therapy on serum antioxidant and lipid status in patients with periodontal disease: preliminary study | |
Rana et al. | STUDY OF MORINGA OLEIFERA HAVING NUTRACEUTICAL PROPERTIES AND THEIR BAKERY PRODUCTS | |
Sonawane | Exploring nutritional values, health claims and allergies associated with kiwifruit consumption. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |